Relationship between 123I-MIBG scintigrams and REM sleep behavior disorder in Parkinson’s disease

Nomura, Takashi; Inoue, Yuichi; Högl, Birgit; Uemura, Yoshiko; Kitayama, Michio; Abe, Takashi; Miyoshi, Hideaki; Nakashima, Kenichiro

doi:10.1016/j.parkreldis.2010.08.011

Cited by 65 publications

(55 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, PD cases with RBD have been found to have more severe abnormalities in 123 I-MIBG scintigraphy than those without RBD [64]. Also discussed above were the findings that PD patients had abnormalities in HRV.…”

Section: Cardiac Abnormalities In Pd Have Been Discussed Above Recenmentioning

confidence: 97%

Premotor Symptoms and Early Diagnosis of Parkinson's Disease

Adler

2011

International Journal of Neuroscience

View full text Add to dashboard Cite

show abstract

Section: Cardiac Abnormalities In Pd Have Been Discussed Above Recenmentioning

confidence: 97%

Premotor Symptoms and Early Diagnosis of Parkinson's Disease

Adler

2011

International Journal of Neuroscience

View full text Add to dashboard Cite

show abstract

“…Also, patients are instructed not to take an antidepressant or chocolate. There is a correlation between RBD and loss of olfaction [22] and loss of MIBG uptake to the cardiac sympathetic nerves [23]. Also, loss of olfaction is correlated with loss of cardiac MIBG uptake [24].…”

Section: Nonmotor Features Of Pdmentioning

confidence: 99%

Recent Research Progress in and Future Perspective on Treatment of Parkinson's Disease

Mizuno

2014

Integr Med Int

View full text Add to dashboard Cite

Background: Clinical features, pathogenesis, and treatment of Parkinson's disease (PD) are reviewed as there has been progress in these areas. Summary: PD is a systemic disease of the nervous system as the initial symptom is related to disturbance of the autonomic nervous system, such as constipation or nocturia. Then, the disease progresses to the brain stem involving the nuclei in the pons and the substantia nigra, and inducing sleep and wakefulness disturbances, affect problems such as anxiety and depression, and motor problems when the disease process has reached the substantia nigra. Furthermore, the disease has an effect on the nucleus basalis of Meynert, the amygdaloid complex and the cerebrum manifesting cognitive impairment. The olfactory pathway is also frequently involved. Key Messages: For the treatment of PD, younger patients without dementia should be treated with a nonergot dopamine agonist first and then with levodopa if necessary. Elderly patients or those with dementia should be treated with levodopa. However, after 5 years of levodopa treatment, many patients with PD develop wearing off. Drugs for the treatment of wearing-off symptoms are reviewed. Many of the patients with wearing-off symptoms develop dyskinesia, and amantadine is so far the only drug that can ameliorate dyskinesia. Because of this situation, a new method of treatment is warranted, such as RNA interaction, according to the author's opinion. Recent progress in this field is also reviewed. i 2014 S. Karger AG, Basel

show abstract

“…Co-occurrence of RBD in PD may represent distinct characteristics of PD: akinetic rigid phenotype, an increased frequency of falls, and a poor response to dopaminergic medications, orthostatic hypotension, and impaired color vision have been described compared with PD patients without RBD [97,98]. A decreased uptake of cardiac MIBG is also reported in PD patients with RBD compared with those without RBD [99,100]. In a prospective study with 42 patients with PD (27 patients with PSG-confirmed RBD and 15 patients without RBD) for 4 years, 48% with RBD developed dementia, compared with 0% of those without RBD, suggesting that RBD was associated with an increased risk of dementia in patients with PD [101].…”

Section: Rapid Eye Movement Sleep Behavior Disordermentioning

confidence: 99%